Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats

International Journal of Cancer

Volumn 140, Issue 12, 2017, Pages 2820-2829

  Van Sebille, Ysabella Z A ^a   Gibson, Rachel J ^a,b   Wardill, Hannah R ^a   Secombe, Kate R ^a   Ball, Imogen A ^a   Keefe, Dorothy M K ^a   Finnie, John W ^c   Bowen, Joanne M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c SA Pathology   (Australia)

Author keywords

dacomitinib; diarrhoea; ErbB; mucositis; TKI

Indexed keywords

ANTINEOPLASTIC AGENT; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIRTECAN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; TX 100; UNCLASSIFIED DRUG; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL VIABILITY; COLON; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DIARRHEA; DISEASE SEVERITY; DRUG CYTOTOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ILEUM DISEASE; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE; WEIGHT GAIN; WISTAR RAT; XTT ASSAY; ANIMAL; CELL SURVIVAL; CHEMICALLY INDUCED; COLORECTAL TUMOR; DISEASE MODEL; DRUG EFFECTS; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENETICS; ILEUM; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERMEABILITY; RADIOIMMUNOPRECIPITATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINE CCL2; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; GENE EXPRESSION; HUMANS; ILEUM; IMMUNOHISTOCHEMISTRY; MALE; PERMEABILITY; QUINAZOLINONES; RADIOIMMUNOPRECIPITATION ASSAY; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 85016420220     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30699     Document Type: Article

References (34)

1. Abdul Razak AR, Soulieres D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 2013;24:761–9.
2. Dietrich E, Antoniades K. Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology. Hippokratia 2012;16:196–9.
3. Hare KJ, Hartmann B, Kissow H, et al. The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res 2007;13:5170–5.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–37.
5. Chen CL, Yu X, James IO, et al. Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis. Lab Invest 2012;92:331–44.
6. Ramalingam SS, Janne PA, Mok T, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:1369–78.
7. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924–32.
8. Van Sebille YZ, Gibson RJ, Wardill HR, et al. Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Support Palliat Care 2016;10:152–6.
9. Van Sebille YZ, Gibson RJ, Wardill HR, et al. ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. Cancer Treat Rev 2015;41:646–52.
10. Lacouture ME, Keefe DM, Sonis S, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol 2016;27:1712–8.
11. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 2008;5:268–78.
12. Bowen JM, Gibson RJ, Cummins AG, et al. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 2006;14:713–31.
13. Wardill HR, Gibson RJ, Van Sebille YZ, et al. A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Exp Biol Med (Maywood) 2016;241:1386–94.
14. Bowen JM, Mayo BJ, Plews E, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther 2012;13:1269–75.
15. Howarth GS, Francis GL, Cool JC, et al. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996;126:2519–30.
16. Wardill HR, Gibson RJ, Van Sebille YZ, et al. Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. Mol Cancer Ther 2016;15:1376–86.
17. Gibson RJ, Bowen JM, Inglis MR, et al. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003;18:1095–100.
18. Keefe DM, Brealey J, Goland GJ, et al. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000;47:632–7.
19. Logan RM, Gibson RJ, Bowen JM, et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008;62:33–41.
20. Bowen JM, Mayo BJ, Plews E, et al. Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemother Pharmacol 2014;74:617–27.
21. Livak F, Schatz DG. Alternative splicing of rearranged T cell receptor delta sequences to the constant region of the alpha locus. Proc Natl Acad Sci USA 1998;95:5694–9.
22. Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2012;9:98–109.
23. Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013;7:162–7.
24. Rasmussen AR, Viby NE, Hare KJ, et al. The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Dig Dis Sci 2010;55:2785–96.
25. Yusta B, Holland D, Koehler JA, et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology 2009;137:986–96.
26. Berlanga-Acosta J, Playford RJ, Mandir N, et al. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut 2001;48:803–7.
27. Goodlad RA, Raja KB, Peters TJ, et al. Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity. Gut 1991;32:994–8.
28. Giri N, Masters JC, Plotka A, et al. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs 2015;33:931–41.
29. Bowen JM. Development of the rat model of lapatinib-induced diarrhoea. Scientifica (Cairo) 2014;2014:194185.
30. Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev 2014;40:917–26.
31. Velandia-Romero ML, Calderon-Pelaez MA, Castellanos JE. In vitro infection with dengue virus induces changes in the structure and function of the mouse brain endothelium. PLoS One 2016;11:e0157786.
32. Wardill HR, Bowen JM, Van Sebille YZ, et al. TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Mol Cancer Ther 2016;15:2767–79.
33. Nakao T, Kurita N, Komatsu M, et al. Irinotecan injures tight junction and causes bacterial translocation in rat. J Surg Res 2012;173:341–7.
34. Schmitz H, Fromm M, Bentzel CJ, et al. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intest nal cell line HT-29/B6. J Cell Sci 1999;112:137–46.